Narrow search
Showing 1 - 10 of 41,628
Cover Image
Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy
Michaeli, Daniel; Michaeli, Christoph T.; Albers, Sebastian - In: The European journal of health economics 25 (2024) 6, pp. 979-997
Persistent link: https://www.econbiz.de/10014633366
Cover Image
Exploring relationship between brand equity and customer loyalty on pharmaceutical market
Dlačić, Jasmina; Kežman, Elvedina - In: Economic and business review : EBR 16 (2014) 2, pp. 121-131
Persistent link: https://www.econbiz.de/10011612102
Cover Image
Umbrella branding in pharmaceutical markets
Suppliet, Moritz - 2017
Persistent link: https://www.econbiz.de/10011734578
Cover Image
Outcome-Based Pricing for New Pharmaceuticals via Rebates
Adida, Elodie - 2019
The price of new brand-name prescription drugs has been rising fast in the US. For example, the Amgen cholesterol drug Repatha had an initial list price of $14,523 per year. Patients, even with insurance coverage, must pay out-of-pocket a significant portion of this price. The treatment might...
Persistent link: https://www.econbiz.de/10012864418
Cover Image
Arzneimittelversorgung und -produktion gefährdet : AMNOG-Reform auf dem Prüfstand
Kirchhoff, Jasmina - 2022
Erstattungsbetragsverhandlungen innovativer Arzneimittel werden als Gefahr für die zukünftige Versorgung der Patienten und für den Forschungs- und … zweckmäßigen Vergleichstherapie gleichwertige Arzneimittel schlechter gestellt werden. Zum anderen können nur noch … Arzneimittel beeinflusst darüber hinaus die Standortentscheidungen pharmazeutischer Unternehmen. …
Persistent link: https://www.econbiz.de/10013468282
Cover Image
Designing Disruption in Pharmaceuticals
Feldman, Robin - 2021
Almost two millennia ago, Archimedes explained that the shortest distance between two points is a straight line. That fundamental principle has been lost in the strange, meandering design of the nation’s pharmaceutical supply system. The result, as Archimedes would have predicted, is...
Persistent link: https://www.econbiz.de/10014087896
Cover Image
Anticompetitive Marketing in the Context of Pharmaceutical Switching in Europe
Domeij, Bengt - 2013
The article deals with the intersection between competition law rules on abuse of a dominant position and switching strategies employed by pharmaceutical originator companies. Switching is also known as ever-greening, product hopping or product life cycle strategies. It is one of the most...
Persistent link: https://www.econbiz.de/10013077034
Cover Image
Umbrella Branding in Pharmaceutical Markets
Suppliet, Moritz - 2017
Umbrella branding is a marketing practice whereby multi-product firms leverage their reputation across different product categories. This paper investigates how advertising in the market of over-the-counter (OTC) drugs affects the decision to buy prescription drugs from a promoted brand name. I...
Persistent link: https://www.econbiz.de/10012947424
Cover Image
Competition between generic and brand name drugs : new evidence from the U.S. pharmaceutical market
Cavaliere, Alberto; Moayedizadeh, Ashin - 2022
Persistent link: https://www.econbiz.de/10014232582
Cover Image
In the name of transparency : organizing European pharmaceutical markets through struggles over transparency devices
Geiger, Susi; Bourgeron, Théo - In: Organization studies : an international … 44 (2023) 11, pp. 1751-1773
Persistent link: https://www.econbiz.de/10014432663